Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 1301 - 1400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1301 | 24962531 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1302 | 24962753 |
US |
32 | 2 |
Device difficult to use, Accidental exposure to product, Wrong technique in product usage process, Drug dose omission by device, Headache, |
||||
ERENUMAB-AOOE, |
||||
| 1303 | 24952688 |
US |
2 | |
Device defective, Accidental exposure to product, Incorrect dose administered by device, |
||||
SECUKINUMAB, SERTRALINE, APIXABAN, |
||||
| 1304 | 24952767 |
US |
35 | 1 |
Product dose omission issue, Device issue, Accidental exposure to product, Device malfunction, Psoriasis, |
||||
GUSELKUMAB, |
||||
| 1305 | 24952922 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1306 | 24952944 |
US |
55 | 1 |
Contusion, Device difficult to use, Incorrect dose administered by device, Accidental exposure to product, Urticaria, Therapy interrupted, Ill-defined disorder, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, RIMEGEPANT SULFATE, |
||||
| 1307 | 24953017 |
US |
24 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1308 | 24953243 |
US |
2 | |
Incorrect dose administered by device, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1309 | 24953245 |
US |
2 | |
Accidental exposure to product, Product leakage, Incorrect dose administered by device, |
||||
SECUKINUMAB, |
||||
| 1310 | 24953314 |
US |
72 | 2 |
Device deployment issue, Product dose omission issue, Accidental exposure to product, Psoriasis, Off label use, Visual impairment, Skin ulcer, |
||||
USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, |
||||
| 1311 | 24953317 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1312 | 24953338 |
US |
71 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1313 | 24953355 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 1314 | 24953433 |
US |
60 | 1 |
Blister, Accidental exposure to product, Product administered at inappropriate site, Product use in unapproved indication, |
||||
| 1315 | 24953527 |
US |
37 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1316 | 24953619 |
CA |
76 | 1 |
Cardiac disorder, Infusion site discharge, Accidental exposure to product, |
||||
HUMAN IMMUNOGLOBULIN G, |
||||
| 1317 | 24953669 |
US |
||
Accidental exposure to product, Occupational exposure to product, Intercepted product preparation error, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 1318 | 24953782 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1319 | 24953808 |
US |
17 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, LISDEXAMFETAMINE DIMESYLATE, |
||||
| 1320 | 24953914 |
US |
58 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1321 | 24953996 |
CA |
34 | 2 |
Syringe issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 1322 | 24954129 |
US |
45 | 1 |
Dysphagia, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1323 | 24954143 |
US |
77 | 2 |
Dry skin, Pruritus, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1324 | 24954267 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1325 | 24954269 |
US |
14 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1326 | 24954282 |
US |
36 | 2 |
Product dose omission issue, Accidental exposure to product, Device deployment issue, Injection site haemorrhage, |
||||
GUSELKUMAB, |
||||
| 1327 | 24954457 |
US |
43 | 2 |
Device difficult to use, Accidental exposure to product, Weight decreased, Drug dose omission by device, Wrong technique in device usage process, |
||||
ERENUMAB-AOOE, |
||||
| 1328 | 24954480 |
US |
37 | 2 |
Product dose omission issue, Device defective, Accidental exposure to product, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 1329 | 24954510 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1330 | 24954713 |
US |
66 | 1 |
Injection site pain, Product preparation error, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1331 | 24954719 |
US |
62 | |
Accidental exposure to product, Device malfunction, Injection site pain, Injection site haemorrhage, Device use issue, |
||||
TEZEPELUMAB-EKKO, |
||||
| 1332 | 24954876 |
US |
31 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1333 | 24955369 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1334 | 24955425 |
US |
23 | 2 |
Device malfunction, Accidental exposure to product, Device issue, Drug dose omission by device, |
||||
SECUKINUMAB, MAGNESIUM, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, FISH OIL, ERGOCALCIFEROL, IRON, ESCITALOPRAM, |
||||
| 1335 | 24955566 |
US |
59 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1336 | 24955568 |
US |
66 | 1 |
Overweight, Asthma, Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, NORTRIPTYLINE HYDROCHLORIDE, |
||||
| 1337 | 24955647 |
US |
76 | 1 |
Injection site pain, Device use error, Accidental exposure to product, Incorrect dose administered by device, |
||||
EVOLOCUMAB, |
||||
| 1338 | 24955656 |
US |
2 | |
Device deployment issue, Exposure via skin contact, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1339 | 24955741 |
US |
16 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1340 | 24955800 |
US |
24 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1341 | 24955804 |
US |
2 | |
Accidental exposure to product, Incorrect dose administered, |
||||
BELIMUMAB, |
||||
| 1342 | 24955815 |
US |
88 | 1 |
Diabetes mellitus, Device difficult to use, Injury associated with device, Accidental exposure to product, Skin abrasion, |
||||
EVOLOCUMAB, |
||||
| 1343 | 24955834 |
CA |
48 | 2 |
Beta haemolytic streptococcal infection, Injection site pain, Injection site discharge, Exposure via skin contact, Accidental exposure to product, Incorrect dose administered by device, Device user interface issue, Patient-device incompatibility, |
||||
ADALIMUMAB-AFZB, ADALIMUMAB-AFZB, ADALIMUMAB-AFZB, GABAPENTIN, OXYCODONE, |
||||
| 1344 | 24956020 |
US |
2 | |
Headache, Accidental exposure to product, Wrong technique in device usage process, Device use issue, |
||||
VARENICLINE, |
||||
| 1345 | 24956157 |
CA |
47 | 1 |
Pneumonia, Device defective, Accidental exposure to product, Incorrect dose administered by device, Wrong technique in product usage process, Nasopharyngitis, Oropharyngeal pain, Cough, Neoplasm skin, Decreased immune responsiveness, |
||||
SECUKINUMAB, SECUKINUMAB, |
||||
| 1346 | 24956195 |
US |
29 | 2 |
Headache, Device difficult to use, Accidental exposure to product, Drug dose omission by device, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 1347 | 24956209 |
US |
2 | |
Drug ineffective, Migraine, Accidental exposure to product, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 1348 | 24956366 |
US |
2 | |
Device issue, Drug dose omission by device, Accidental exposure to product, Condition aggravated, Device malfunction, |
||||
OFATUMUMAB, OFATUMUMAB, |
||||
| 1349 | 24956850 |
US |
5 | 2 |
Drug screen positive, Accidental exposure to product, |
||||
FENTANYL, |
||||
| 1350 | 24957199 |
US |
2 | |
Injection site discharge, Needle issue, Drug dose omission by device, Injection site erythema, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB, |
||||
| 1351 | 24957334 |
GR |
31 | 1 |
Pneumonia, Accidental exposure to product, Incorrect dose administered, Device issue, |
||||
BIMEKIZUMAB, |
||||
| 1352 | 24946374 |
US |
76 | 1 |
Device leakage, Accidental exposure to product, Off label use, |
||||
GOLIMUMAB, |
||||
| 1353 | 24946500 |
US |
58 | 2 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, Underdose, Wrong technique in device usage process, |
||||
MEPOLIZUMAB, |
||||
| 1354 | 24946509 |
CA |
45 | 1 |
Off label use, Device defective, Product dose omission issue, Accidental exposure to product, |
||||
GOLIMUMAB, |
||||
| 1355 | 24946822 |
US |
58 | 2 |
Injury associated with device, Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 1356 | 24946851 |
US |
63 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1357 | 24946985 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1358 | 24947017 |
US |
1 | |
Accidental exposure to product, Circumstance or information capable of leading to medication error, Exposure via skin contact, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 1359 | 24947033 |
US |
42 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1360 | 24947142 |
US |
2 | |
Drug dose omission by device, Accidental exposure to product, Device leakage, Exposure via skin contact, Device defective, |
||||
SECUKINUMAB, |
||||
| 1361 | 24947454 |
US |
70 | 1 |
Oropharyngeal pain, Pruritus, Burning sensation, Vision blurred, Dysgeusia, Product after taste, Accidental exposure to product, Exposure via skin contact, Patient dissatisfaction with treatment, Wrong dose, Product delivery mechanism issue, Wrong technique in product usage process, Product packaging difficult to open, Liquid product physical issue, Product use complaint, Product deposit, |
||||
LIFITEGRAST, |
||||
| 1362 | 24947464 |
US |
2 | |
Hair growth abnormal, Accidental exposure to product, Poor quality product administered, Product container issue, Product physical consistency issue, |
||||
MINOXIDIL, MINOXIDIL, |
||||
| 1363 | 24947480 |
US |
2 | |
Skin discolouration, Exposure via skin contact, Accidental exposure to product, Wrong technique in product usage process, |
||||
| 1364 | 24947531 |
US |
86 | 2 |
Avian influenza, COVID-19, Rash erythematous, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, CALCIUM, GABAPENTIN, FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE ORAL, FEXOFENADINE HCL, MAGNESIUM GLYCINATE, ERGOCALCIFEROL, ALPRAZOLAM, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, AMLODIPINE BESYLATE, FENOFIBRATE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, OSELTAMIVIR PHOSPHATE, OSELTAMIVIR ACID, OSELTAMIVIR, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, MUPIROCIN, MUPIROCIN CALCIUM, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, |
||||
| 1365 | 24947539 |
US |
71 | 2 |
Injection site haemorrhage, Injection site pain, Incorrect dose administered by device, Device use error, Product communication issue, Accidental exposure to product, Incorrect disposal of product, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 1366 | 24948160 |
FR |
1 | |
Device deployment issue, Off label use, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 1367 | 24948184 |
US |
2 | |
Accidental exposure to product, Poor quality product administered, Product container issue, |
||||
MINOXIDIL, MINOXIDIL, |
||||
| 1368 | 24948322 |
US |
2 | |
Drug dose omission by device, Accidental exposure to product, Injection site pain, |
||||
SECUKINUMAB, |
||||
| 1369 | 24948342 |
US |
1 | |
Accidental exposure to product, Device issue, |
||||
SECUKINUMAB, |
||||
| 1370 | 24948344 |
US |
2 | |
Eye pain, Accidental exposure to product, |
||||
MINOXIDIL, |
||||
| 1371 | 24948401 |
US |
1 | |
Accidental exposure to product, Incorrect dose administered, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 1372 | 24948711 |
US |
69 | 2 |
Off label use, Device issue, Accidental exposure to product, Product quality issue, Bladder disorder, Inappropriate schedule of product administration, |
||||
TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, |
||||
| 1373 | 24949977 |
US |
2 | 2 |
Accidental exposure to product, |
||||
OXYCODONE HYDROCHLORIDE, OXYCODONE, FENTANYL, |
||||
| 1374 | 24950565 |
CO |
46 | 2 |
Syringe issue, Product dose omission issue, Accidental exposure to product, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 1375 | 24951049 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1376 | 24951050 |
US |
73 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1377 | 24951107 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1378 | 24951138 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1379 | 24951178 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1380 | 24951189 |
US |
11 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1381 | 24951224 |
US |
25 | 1 |
Dermatitis, Influenza like illness, Cough, Nasal congestion, Rash macular, Erythema, Pruritus, Condition aggravated, Pollakiuria, Product use in unapproved indication, Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1382 | 24951225 |
US |
15 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1383 | 24951866 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1384 | 24951895 |
US |
40 | 1 |
Vision blurred, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1385 | 24951903 |
US |
5 | |
Device deployment issue, Accidental exposure to product, Inappropriate schedule of product administration, Wrong technique in product usage process, Incorrect dose administered, |
||||
GUSELKUMAB, |
||||
| 1386 | 24952030 |
US |
23 | 1 |
Accidental exposure to product, |
||||
MORPHINE SULFATE, FENTANYL, |
||||
| 1387 | 24952303 |
DE |
45 | 2 |
Device deployment issue, Product dose omission issue, Accidental exposure to product, Psoriasis, |
||||
GUSELKUMAB, |
||||
| 1388 | 24952398 |
US |
1 | |
Accidental exposure to product, Needle issue, Incorrect dose administered by device, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 1389 | 24952496 |
US |
2 | |
Accidental exposure to product, Device leakage, Device malfunction, Exposure via skin contact, |
||||
SECUKINUMAB, |
||||
| 1390 | 24952559 |
US |
73 | 1 |
Injection site pain, Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1391 | 24952594 |
US |
2 | |
Injection site pain, Wrong technique in device usage process, Accidental exposure to product, Product complaint, |
||||
BELIMUMAB, |
||||
| 1392 | 24945467 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 1393 | 24945500 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 1394 | 24945513 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1395 | 24945587 |
US |
38 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 1396 | 24945620 |
US |
53 | 2 |
Pain, Accidental exposure to product, Device difficult to use, |
||||
ETANERCEPT, |
||||
| 1397 | 24945680 |
US |
2 | |
Brain fog, Incorrect dose administered, Fatigue, Accidental exposure to product, Wrong technique in product usage process, |
||||
FREMANEZUMAB-VFRM, |
||||
| 1398 | 24945687 |
US |
35 | 2 |
Contusion, Urticaria, Condition aggravated, Injection site pain, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1399 | 24945719 |
US |
32 | 2 |
Device leakage, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 1400 | 24945758 |
US |
74 | 2 |
Eye swelling, Circumstance or information capable of leading to medication error, Accidental exposure to product, Exposure via skin contact, Intentional product use issue, Product complaint, Product delivery mechanism issue, |
||||
PERFLUOROHEXYLOCTANE, EVOLOCUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28